ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global in 2021. by Nannan Qian (10650782)

Driving variables recorded from the simulator. by Mobina Faqani (22783963)

“…Additionally, HF conversation was associated with a decrease in ART among conservative participants, while it significantly increased TIBL for both moderate and conservative groups. …”

Innovative Self-Powered Electrically Stimulated Fabric Dressing for Enhanced Diabetic Wound Healing by Lin He (102807)

“…To address these challenges, we have developed a novel self-powered electrical stimulation fabric dressing (SESFD). …”

Methodological workflow used in the study. by Ajit Kumar Rudra (21647706)

“…From the analysis it was observed that the forest cover showed a major variation with the interval, decreasing from 234634 ha (76%) in 1988 to 168476 ha (54%) in 2019 with an annual loss of 2134.13 ha/year. …”

FAT1 interacts with the E3 ligase MIB2. by Rui Li (4631)

Study methods flow chart. by Luis Polo-Ferrero (20513578)

“…Hormonal changes that occur early in women may influence protein synthesis and promote muscle atrophy, leading to probable sarcopenia, defined as a loss of muscle strength without an obvious decrease in muscle mass. …”

(a) Carbon emissions (%) as a function of temperature for the integrated and control systems. (b) Output mass of biochar (g) at various temperatures for the integrated and control... by Ning Zuo (17295415)

Summary of related studies. by Most. Fatematuz Zohora (19429152)

“…Traditional methods like the Banker’s algorithm provide solutions but suffer from limitations such as static process handling, high time complexity, and a lack of real-time adaptability. To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”

Time complexity of different safety algorithms. by Most. Fatematuz Zohora (19429152)

“…Traditional methods like the Banker’s algorithm provide solutions but suffer from limitations such as static process handling, high time complexity, and a lack of real-time adaptability. To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”

Process execution halted due to deadlock. by Most. Fatematuz Zohora (19429152)

“…Traditional methods like the Banker’s algorithm provide solutions but suffer from limitations such as static process handling, high time complexity, and a lack of real-time adaptability. To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”

Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions. by Razieh Bidhendi-Yarandi (7139387)

Table 1_Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combinati... by Teng Zhang (457128)

“…Background<p>Recent advancements in combination therapy for unresectable hepatocellular carcinoma (uHCC) have shown promise, but reliable serological prognostic indicators are currently lacking for patients undergoing triple combination therapy of stereotactic body radiation therapy (SBRT), immunotherapy, and targeted therapy. We aimed to investigate the prognostic significance of early alpha fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) responses in these patients.…”

Fig 3 - by Razieh Bidhendi-Yarandi (7139387)

Heatmap analysis for technical reproducibility of Cohort #1 CP dataset (28wk-old WT and R14^Δ/+). by Brian Foo (19273132)

Structural clashes in TP53 mutants: (A) G266E mutation causes steric clashes with PHE109 and LEU257, destabilizing the structure. by Ashraf Attia Mahmoud (21262201)

Impact of temperature on efflux pump inhibitors in mediating ethidium bromide accumulation in <i>Mycobacterium abscessus</i>. by Timilehin Faboro (20175963)

Specifications of prototypes of RSSCA system. by Ngoc-Hai Vu (22290844)

“…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”